Evidence map›Paper›PMID 40874328›Full record

ArticleHaematologica2026

Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed/refractory multiple myeloma: results from the French real-world EMMY study.

Thomas Chalopin, Cyrille Hulin, Bruno Royer, Jean-Noel Bastie, Arthur Bobin, Karim Belhadj Merzoug, Margaret Macro, Lionel Karlin, Caroline Jacquet, Mohamad Mohty and 13 more

Abstract read
In one paragraph

Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Thomas ChalopinService d'hématologie et Thérapie Cellulaire, Centre Hospitalier Universitaire (CHU) Tours, Hôpital Bretonneau, Tours.
Cyrille HulinService d'hématologie, Hôpital Haut Lévêque, Pessac.
Bruno RoyerService d'hématologie, Hôpital Saint-Louis, Paris.
Jean-Noel BastieHématologie Clinique, CHU Dijon Bourgogne, Dijon.
Arthur BobinService d'hématologie, Hôpital Poitiers, Poitiers.
Karim Belhadj MerzougUnité Fonctionnelle Hémopathies Lymphoïdes, CHU Henri Mondor, Créteil.
Margaret MacroService d'hématologie, Hôpital Caen, Caen.
Lionel KarlinService d'hématologie, Hôpital Lyon, Lyon.
Caroline JacquetCHU de Nancy, Vandoeuvre les Nancy.
Mohamad MohtySorbonne University, Saint-Anne Hospital (APHP), INSERM UMRS-938, Paris.
Laurent FrenzelService d'hématologie, Hôpital Necker, Paris.
Cécile SonntagHôpital Hautepierre, Strasbourg.
Jean FontanService d'hématologie, Centre Hospitalier Régional Universitaire Jean Minjoz, Besançon.
Sophie RigaudeauService d'hématologie, Centre Hospitalier de Versailles André Mignot, Le Chesnay.
Murielle RousselHématologie clinique, CHU de Limoges, Hospital Dupuytren, Limoges.
Laurence SanhesCentre Hospitalier Perpignan, Perpignan.
Driss ChaouiHôpital Victor Dupouy, Argenteuil.
Laure VincentDépartement d'hématologie clinique, Hôpital Saint Eloi, CHU de Montpellier.
Hubert OrfeuvreHôpital de Fleyriat, Bourg en Bresse.
Malek BouketoucheCentre Hospitalier Saint- Quentin, Saint Quentin.
Ronan GarlantezecSanté publique et épidémiologie, CHU de Rennes, Rennes.
Olivier DecauxService d'hématologie, Hôpital Rennes, Rennes.
Aurore PerrotService d'hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40874328
PMCPMC12862309

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.